{"id":33295,"date":"2013-06-21T10:57:27","date_gmt":"2013-06-21T14:57:27","guid":{"rendered":"http:\/\/asweetlife.org\/?post_type=news&#038;p=33295"},"modified":"2015-12-30T03:21:01","modified_gmt":"2015-12-30T08:21:01","slug":"jdrf-announces-two-partnerships-to-develop-pumpable-glucagon-for-artificial-pancreas-systems","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=33295","title":{"rendered":"JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas Systems"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-32724 lazyload\" title=\"JDRF New Logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg\" alt=\"\" width=\"179\" height=\"97\" \/><\/a>JDRF has announced partnerships with both Xeris Pharmaceuticals, Inc., and LATITUDE Pharmaceuticals, Inc. (LPI), to support the development soluble glucagon formulations\u2014an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).<\/p>\n<p style=\"text-align: justify;\">First-generation artificial pancreas systems currently being tested in JDRF-supported outpatient clinical trials use technologies already available; they combine a continuous glucose monitor (CGM) with an insulin pump using computer software, to partially automate the right amount of insulin delivery at the right times for people with T1D.<\/p>\n<p style=\"text-align: justify;\">\u201cStudies have demonstrated the game-changing value of first generation artificial pancreas systems in improving blood-glucose control and alleviating some of the burdens of managing type 1 diabetes,\u201d said Sanjoy Dutta, Ph.D., JDRF\u2019s senior director of treat therapies. \u201cStill, future generation artificial pancreas systems are expected to do even more. To become fully automated, closed loop systems, new technologies and drugs\u2014including stable, pumpable glucagon\u2014will be required in order to more closely and accurately mimic the functions of a healthy pancreas. Both near-term and long-term projects to advance the artificial pancreas are important research priorities for JDRF.\u201d<\/p>\n<p style=\"text-align: justify;\">While first-generation artificial pancreas systems will deliver insulin, one of the aspects of future generations will be their ability to deliver multiple hormones, such as glucagon. Glucagon is a naturally occurring hormone that raises blood-sugar levels to prevent hypoglycemia (low blood sugar), but its regulation is impaired in people with T1D, for whom hypoglycemia can be dangerous. In a healthy pancreas, it complements the function of insulin to provide the natural fine-tuning of blood-glucose control, and previous studies supported by JDRF and others have shown that the addition of glucagon to insulin treatment in T1D reduces the frequency of hypoglycemia.<\/p>\n<p style=\"text-align: justify;\">One major hurdle in developing an advanced generation, multi-hormonal artificial pancreas system is that commercially available glucagon does not remain stable; the powder and solution mix into a short-lived liquid form not suitable for long-term use in a pump. Xeris and LPI will develop two different approaches to making glucagon usable for infusion pumps.<\/p>\n<p style=\"text-align: justify;\">Xeris\u2014a specialty pharmaceutical company based in Austin, TX, focused on developing injectable therapeutics\u2014will study its stable, room-temperature, and non-aqueous injectable glucagon (G-Pump\u2122 Glucagon) to treat hypoglycemia. Clinical studies will take place at Oregon Health &amp; Science University (OHSU) with two years of milestone-based funding from JDRF.<\/p>\n<p style=\"text-align: justify;\">\u201cOur partnership with JDRF enables us to move forward in pursuing an improved approach to controlling blood glucose levels\u00a0 by enabling a fully closed loop system that addresses\u00a0 both hyperglycemia and hypoglycemia,\u201d said Steve Prestrelski, Ph.D., chief executive officer at Xeris. \u201cWe look forward to working with JDRF to make this a successful program.\u201d<\/p>\n<p style=\"text-align: justify;\">LPI\u2014a drug formulation development company based in San Diego, CA\u2014will use a unique, proprietary, solvent-free, glucagon nanoemulsion (Nano-G) to solubilize and stabilize the molecule, such that it is not vulnerable to degradation and remains biologically active. With milestone-based funding from JDRF for one year, LPI plans to begin clinical testing in the United States in 2014.<\/p>\n<p style=\"text-align: justify;\">\u201cLATITUDE is truly honored to partner with a prestigious and leading organization such as JDRF,\u201d said Andrew Chen, Ph.D., LPI\u2019s president. \u201cThis partnership will accelerate LATITUDE\u2019s stable, soluble glucagon formulation and its potential for new medical applications. Our partnership with JDRF will give us an opportunity to provide a missing piece needed to make the bi-hormonal artificial pancreas a reality.\u201d<\/p>\n<p style=\"text-align: justify;\">Both Xeris and LPI are using approaches distinct from the\u00a0<a href=\"http:\/\/jdrf.org\/press-releases\/stable-liquid-glucagon-formulation-discovered-for-potential-use-in-artificial-pancreas-systems\/\" target=\"_blank\">ongoing JDRF-supported research program led by W. Kenneth Ward<\/a>, M.D. at OHSU, which is utilizing a liquid solution of glucagon at a high pH in order to stabilize the drug.<\/p>\n<p style=\"text-align: justify;\">Source: <a href=\"http:\/\/jdrf.org\/press-releases\/\" target=\"_blank\">JDRF<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>JDRF has announced a two partnerships to support the development soluble glucagon formulations\u2014an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).<\/p>\n","protected":false},"author":131,"featured_media":32724,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1448],"tags":[415,287],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas<\/title>\n<meta name=\"description\" content=\"JDRF has announced two partnerships to support the development soluble glucagon formulations\u2014an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=33295\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=33295\",\"url\":\"https:\/\/asweetlife.org\/?p=33295\",\"name\":\"JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=33295#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=33295#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg\",\"datePublished\":\"2013-06-21T14:57:27+00:00\",\"dateModified\":\"2015-12-30T08:21:01+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"JDRF has announced two partnerships to support the development soluble glucagon formulations\u2014an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=33295#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=33295\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=33295#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg\",\"width\":179,\"height\":97,\"caption\":\"JDRF New Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=33295#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas Systems\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas","description":"JDRF has announced two partnerships to support the development soluble glucagon formulations\u2014an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=33295","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=33295","url":"https:\/\/asweetlife.org\/?p=33295","name":"JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=33295#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=33295#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg","datePublished":"2013-06-21T14:57:27+00:00","dateModified":"2015-12-30T08:21:01+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"JDRF has announced two partnerships to support the development soluble glucagon formulations\u2014an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=33295#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=33295"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=33295#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2013\/05\/JDRF-New-Logo.jpg","width":179,"height":97,"caption":"JDRF New Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=33295#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"JDRF Announces Two Partnerships to Develop Pumpable Glucagon for Artificial Pancreas Systems"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/33295"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33295"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/33295\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/32724"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}